Drug development

#Clinical trials #Drug development #FDA

FDA grant ODD for hyperammonemia in inborn errors of metabolism

Versantis’ lead product candidate VS-01 has been has granted orphan drug designation (ODD) by the Food and Drug Administration (FDA) for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM).   “This orphan drug designation from the FDA validates the scientific rationale of VS-01 in a… Read More

#News

#Clinical trial #Drug development #Drug discovery #Drug targets

Data shows promise for patients with asthma and comorbid nasal polyps 

New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1   Tezepelumab is a potential first-in-class treatment that acts by targeting thymic stromal lymphopoietin (TSLP), an… Read More

#News

#Drug development #Neurodegenerative disorders #Neuroscience #Parkinson's #Pharmaceuticals

Partnership for commercialisation of Parkinson’s drug in Europe 

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.  Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves… Read More

#News

#Biopharmaceuticals #Drug development #Webinar

Webinar: learn how to accelerate biosimilar development

Using an automated CE-SDS platform in efficient biosimilar comparability studies is a free-to-attend webinar which will be hosted by DDW and supported by Bio-Techne on 29 September at 4PM BST. Watch on Demand here. Join Dr Richard L Easton, Technical Director of Structural Analysis at BioPharmSpec as he discusses… Read More

#News #Trending News

#Drug development #Oncology #Therapeutics

Avacta appoints Chief Scientific Officer of therapeutics division

Avacta has appointed Dr Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. Dr McLaughlin is an experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical… Read More

#Business & Investment #News

#Biopharmaceuticals #Clinical trials #Drug development #Drug discovery

Building a pipeline of clinically-differentiated cancer therapies 

As previously reported by DDW, Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. Megan Thomas speaks Dr Alastair Smith, Chief Executive Officer of Avacta Group, about this development.   MT: You previously commented that this study marks the… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Drug development #Drug discovery #Podcast #Therapeutics

How Bamlanivimab reached clinic in eight months – podcast 

The latest DDW Sponsored Sitting Down With podcast features Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Co and Dan Bedinger, Application Science Team Lead, Carterra. Bamlanivimab was the first neutralising monoclonal antibody to receive emergency use authorisation from the FDA as a treatment for mild… Read More

#Covid-19 #News

#Biomedicine #Cell and gene therapy #Drug development

BioIVT launches human AB serum for cell and gene therapy development 

BioIVT’s human AB serum product line is designed to supplement cell culture media and facilitate cell and gene therapy development.  Human AB serum contains many compounds that are vital for cell growth, including growth factors, vitamins, nutrients, trace elements and transport factors. As a result, human… Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Institute of Cancer Research

New cancer drug to enter first clinical trial targeting HSF1 pathway 

The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma.  The investigational oral drug inhibits the so-called… Read More

#Cancer Research #Trending News

#Biopharmaceutical #Clinical trials #Drug delivery #Drug development

First patient dosed in izokibep trial for patients with active AS

Inmagene Biopharmaceuticals and Affibody have dosed the first patient in the global ASPIRE Phase II trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis (AS).  “Dosing the first patient in the global Phase II AS trial is an important milestone for the izokibep programme,” said Dr. Jean-Louis Saillot, Inmagene’s Chief… Read More

#News

#Assays #Cell and gene therapy #Drug development #Immunology

Collaboration agreement for ImmunoBiopsy platform 

Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to deploy Savicell’s patented ImmunoBiopsy immunometabolism platform. The aim is to develop and validate diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing of its cell and gene therapies. New assays will be developed to enhance the potency of cell and gene therapies… Read More

#Business & Investment #News

#Clinical trials #Diabetes #Drug development #Eye

Scientists prepare to trial new nano-drug for eye diseases 

Professor Di Yu of the UQ Diamantina Institute collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang Hospital to address age-related macular degeneration and retinal neovascularisation linked to diabetes, which affect approximately 450 million people worldwide. This has been published in Nature Biomedical Engineering.  Currently, treatments… Read More

#News

#AI #Drug development #Immuno-oncology #Machine learning #Oncology

Bristol Myers Squibb develops Exscientia’s drug candidate 

Exscientia has announced that Bristol Myers Squibb has elected to in-license its immune-modulating drug candidate. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.  The in-licensed candidate targets… Read More

#Cancer Research #News

#Cell therapy #Diabetes #Drug development #Immunology #Life sciences

Dundee professor joins GSK’s Immunology Network 

Professor of Cellular Immunology at the University of Dundee’s School of Life Sciences, Doreen Cantrell, has been selected to join GSK’s Immunology Network, a programme designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology. … Read More

#News

#Biologics / Biotechnology #Collaboration #Drug development

Collaboration aims to accelerate cyro-EM research 

Amgen and the University of Southern California (USC) are working together to provide researchers access to two cryo-transmission electron microscopes (cryo-EMs) – the Thermo Scientific Krios and Glacios.  Access to the two instruments in one shared location allows researchers from both institutions to combine resources to bring more speed and… Read More

#News

#Clinical trials #Drug development #Drug discovery

Lung fibrosis drug may help heart failure patients 

An early phase trial of pirfenidone, a drug currently used to treat lung fibrosis, has shown it may also help patients who suffer from a common form of heart failure in a study funded by the National Institute for Health Research, published in Nature Medicine.  Trialed in… Read More

#News